Clinical Trial Update: To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients [Phase 1]

View source ↗

Summary

Phase 1 study evaluating CGRP blockade with AMG 334 for preventing PACAP-38–induced migraine-like attacks in migraine patients has completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• AMG 334 (erenumab)

Snippet

Sponsor: Amgen | Conditions: Migraine | Phase 1 | Status: COMPLETED | Results posted: 2019-06-03